Eva Montanari

Dr. Eva Montanari

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
Giovanni TossettaGiovanni Tossetta
Giovanni Tossetta
SFSonia Fantone
Sonia Fantone
EMEva Montanari
Eva Montanari
Daniela MarzioniDaniela Marzioni
Daniela Marzioni
GGGaia Goteri
Gaia Goteri
Among gynaecologic malignancies, ovarian cancer is one of the most dangerous, with a high fatality rate and relapse due to the occurrence of chemoresistance. Many researchers demonstrated that oxidative stress is involved in tumour occurrence, growth and development. Nuclear factor erythroid 2-related factor 2 (NRF2) is an important transcription factor, playing an important role in protecting against oxidative damage. Increased levels of Reactive Oxygen Species (ROS) activate NRF2 signalling, inducing the expression of antioxidant enzymes, such as haem oxygenase (HO-1), catalase (CAT), glutathione peroxidase (GPx) and superoxide dismutase (SOD), that protect cells against oxidative stress. However, NRF2 activation in cancer cells is responsible for the development of chemoresistance, inactivating drug-mediated oxidative stress that normally leads to cancer cells’ death. In this review, we report evidence from the literature describing the effect of NRF2 on ovarian cancer, with a focus on its function in drug resistance, NRF2 natural and synthetic modulators and its protective function in normal ovarian preservation.

Verified
Journal Article
Open access
PDF file
GDGloria Daziani
Gloria Daziani
AFAlfredo Fabrizio Francesco Lo Faro
Alfredo Fabrizio Francesco Lo Faro
VMVincenzo Montana
Vincenzo Montana
GGGaia Goteri
Gaia Goteri
MPmauro pesaresi
mauro pesaresi
ANGELO MONTANAANGELO MONTANA
ANGELO MONTANA
According to the EU Early Warning System (EWS), synthetic cathinones (SCs) are the second largest new psychoactive substances (NPS) class, with 162 synthetic cathinones monitored by the EU EWS. They have a similar structure to cathinone, principally found in Catha Edulis; they have a phenethylamine related structure but also exhibit amphetamine-like stimulant effects. Illegal laboratories regularly develop new substances and place them on the market. For this reason, during the last decade this class of substances has presented a great challenge for public health and forensic toxicologists. Acting on different systems and with various mechanisms of action, the spectrum of side effects caused by the intake of these drugs of abuse is very broad. To date, most studies have focused on the substances’ cardiac effects, and very few on their associated neurotoxicity. Specifically, synthetic cathinones appear to be involved in different neurological events, including increased alertness, mild agitation, severe psychosis, hyperthermia and death. A systematic literature search in PubMed and Scopus databases according to PRISMA guidelines was performed. A total of 515 studies published from 2005 to 2022 (350 articles from PubMed and 165 from Scopus) were initially screened for eligibility. The papers excluded, according to the criteria described in the Method Section (n = 401) and after full text analyses (n = 82), were 483 in total. The remaining 76 were included in the present review, as they met fully the inclusion criteria. The present work provides a comprehensive review on neurotoxic mechanisms of synthetic cathinones highlighting intoxication cases and fatalities in humans, as well as the toxic effects on animals (in particular rats, mice and zebrafish larvae). The reviewed studies showed brain-related adverse effects, including encephalopathy, coma and convulsions, and sympathomimetic and hallucinogenic toxidromes, together with the risk of developing excited/agitated delirium syndrome and serotonin syndrome.

Verified
Journal Article
Open access
PDF file
ATAnnagiulia Di Trana
Annagiulia Di Trana
DBDiletta Berardinelli
Diletta Berardinelli
EMEva Montanari
Eva Montanari
Paolo BerrettaPaolo Berretta
Paolo Berretta
Giuseppe BasileGiuseppe Basile
Giuseppe Basile
Francesco P. Busardó Francesco P. Busardó
Francesco P. Busardó
Adulteration is a well-known practice of drug manufacturers at different stages of drug production. The intentional addition of active ingredients to adulterate the primary drug may enhance or mask pharmacological effects or may produce more potent drugs to increase the number of available doses and the dealer’s profit. Adulterants found in different drugs change over time in response to different factors. A systematic literature search in PubMed and Scopus databases and official international organizations’ websites according to PRISMA guidelines was performed. A total of 724 studies were initially screened, with 145 articles from PubMed and 462 from Scopus excluded according to the criteria described in the Method Section. The remaining 117 records were further assessed for eligibility to exclude articles without sufficient data. Finally, 79 studies were classified as “non-biological” (n = 35) or “biological” (n = 35 case reports; n = 9 case series) according to the samples investigated. Although the seized samples analyses revealed the presence of well-established adulterants such as levamisole for cocaine or paracetamol/acetaminophen for heroin, the reported data disclosed new adulteration practices, such as the use of NPS as cutting agents for classic drugs of abuse and other NPS. For example, heroin adulterated with synthetic cannabinoids or cocaine adulterated with fentanyl/fentalogues raised particular concern. Notably, adulterants play a role in some adverse effects commonly associated with the primary drug, such as levamisole-adulterated cocaine that may induce vasculitis via an autoimmune process. It is essential to constantly monitor adulterants due to their changing availability that may threaten drug consumers’ health.

8 February 2023 in Biology
Verified
Journal Article
Open access
PDF file
AFAlfredo Fabrizio Francesco Lo Faro
Alfredo Fabrizio Francesco Lo Faro
DBDiletta Berardinelli
Diletta Berardinelli
TCTommaso Cassano
Tommaso Cassano
GDGregory Dendramis
Gregory Dendramis
EMEva Montanari
Eva Montanari
MHMarilyn Ann Huestis
Marilyn Ann Huestis
In January 2020, the World Health Organization (WHO) issued a Public Health Emergency of International Concern, declaring the COVID-19 outbreak a pandemic in March 2020. Stringent measures decreased consumption of some drugs, moving the illicit market to alternative substances, such as New Psychoactive Substances (NPS). A systematic literature search was performed, using scientific databases such as PubMed, Scopus, Web of Science and institutional and government websites, to identify reported intoxications and fatalities from NPS during the COVID-19 pandemic. The search terms were: COVID-19, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, coronavirus disease 2019, intox*, fatal*, new psychoactive substance, novel psychoactive substance, smart drugs, new psychoactive substance, novel synthetic opioid, synthetic opioid, synthetic cathinone, bath salts, legal highs, nitazene, bath salt, legal high, synthetic cannabinoid, phenethylamine, phencyclidine, piperazine, novel benzodiazepine, benzodiazepine analogue, designer benzodiazepines, tryptamine and psychostimulant. From January 2020 to March 2022, 215 NPS exposures were reported in Europe, UK, Japan and USA. Single NPS class intoxications accounted for 25, while mixed NPS class intoxications represented only 3 cases. A total of 130 NPS single class fatalities and 56 fatalities involving mixed NPS classes were published during the pandemic. Synthetic opioids were the NPS class most abused, followed by synthetic cathinones and synthetic cannabinoids. Notably, designer benzodiazepines were frequently found in combination with fentalogues. Considering the stress to communities and healthcare systems generated by the pandemic, NPS-related information may be underestimated. However, we could not define the exact impacts of COVID-19 on processing of toxicological data, autopsy and death investigations.

1 September 2018 in World Neurosurgery
Verified
Journal Article
Closed access
EMEva Montanari
Eva Montanari
GPGabriele Polonara
Gabriele Polonara
RMRoberto Montalti
Roberto Montalti
MVMarco Vivarelli
Marco Vivarelli
RRRiccardo Antonio Ricciuti
Riccardo Antonio Ricciuti
ATAdriano Tagliabracci
Adriano Tagliabracci

18 May 2019 in Forensic Science International
Verified
Journal Article
Closed access
Francesco P. Busardó Francesco P. Busardó
Francesco P. Busardó
ATAnnagiulia Di Trana
Annagiulia Di Trana
EMEva Montanari
Eva Montanari
SMSimona Mauloni
Simona Mauloni
ATAdriano Tagliabracci
Adriano Tagliabracci
RGRaffaele Giorgetti
Raffaele Giorgetti